A new study reveals there is little evidence that substances that claim to reduce the effects of alcohol-induced hangovers work.
Researchers have identified a rare population of potentially toxic senescent cells that may be a novel target for Alzheimer's disease therapies.
Researchers have refined a molecule that shows promise for the prevention of Parkinson's disease.
Sildenafil, an FDA-approved drug to treat erectile dysfunction (Viagra) and pulmonary hypertension, appears to be a promising candidate to prevent and treat Alzheimer's disease.
A drug currently being tested in cancer clinical trials appears to prevent dysfunction in an immune cell signaling pathway associated with Alzheimer's disease. Blocking the pathway could prevent Alzheimer's from developing and slow the progression of symptoms for those who already have the disease.
A growing body of evidence suggests psychedelics including psilocybin and LSD show promise in providing lasting relief from symptoms for those suffering some mental health disorders. Researchers found DOI, a similar drug to LSD, reduced negative behavioral responses following fear triggers in mouse models of anxiety.
The extracts of certain plants long used by Native Americans as topical analgesics activate the KCNQ2/3 potassium channel. The compounds provide pain relief and prevent diarrhea.
Dasatinib, an FDA-approved drug for chronic myeloid leukemia, and an experimental drug for liver cancer reduced neuroinflammation, tau phosphorylation, and amyloid secretion in cell cultures of post-mortem brain samples of those with the APOE4 Alzheimer's associated gene.
Combining neuroimaging and artificial intelligence, researchers identified novel brain signatures unique to the response of each antidepressant.
Combining Disulfiram, a medication commonly used to treat chronic alcoholism, with copper ions kills medulloblastoma cancer cells and prevents new ones from growing.